Zura Bio Ltd
No SEC Form 4 filings for $ZURA in the last 30 days.
See all $ZURA insider activity →Zura Bio reported a net loss of $25.8M for 3Q 2026, up 43% from the prior-year quarter, with no product sales revenue. Diluted loss per share narrowed to $0.20. The company completed enrollment in two Phase 2 trials and expects results in 2026 and 2027. The FDA cleared a Phase 2 study for polymyalgia rheumatica, planned for year-end 2026.
Zura Bio Ltd (ZURA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Zura Bio Reports Third Quarter 2026 Financial Results and Recent Corporate Updates • TibuSHIELD topline data in hidradenitis suppurativa (HS) remains on track for Q4 2026; enrollment completed with 247 participants randomized, exceeding target • TibuSURE topline data
Zura Bio (ZURA) reported a Q3 2026 net loss of $25.8M ($0.20/share) and had $187.7M in cash, expected to last through 2028. The company anticipates data catalysts in 2027 and a Phase 2 study for tibulizumab.
Over the past 7 days, AlphAI's AI scored 2 news stories mentioning ZURA (Zura Bio Ltd). Coverage has been balanced: 1 bullish, 0 neutral, and 1 bearish.
Recent ZURA coverage spans earnings, financial news and technology.
The widened loss and lack of revenue pressure the stock lower, while trial completions may offer upside if data are positive.
Positive trial progress and ample cash runway likely support upside pressure on ZURA.
Zura Bio (ZURA) reported a Q3 2026 net loss of $25.8M ($0.20/share) and had $187.7M in cash, expected to last through 2028. The company anticipates data catalysts in 2027 and a Phase 2 study for tibulizumab.
Analyst upgrade with a high price target may drive buying interest.
The enrollment milestones may boost short‑term optimism, but the expanding loss raises cash‑flow concerns.
AlphAI scores every news story that mentions ZURA with an AI model for sentiment and relevance, and aggregates insider trades from Zura Bio Ltd's SEC EDGAR Form 4 filings. Figures refresh continuously.
Zura Bio reported a net loss of $25.8M for 3Q 2026, up 43% from the prior-year quarter, with no product sales revenue. Diluted loss per share narrowed to $0.20. The company completed enrollment in two Phase 2 trials and expects results in 2026 and 2027. The FDA cleared a Phase 2 study for polymyalgia rheumatica, planned for year-end 2026.
1 min readZura Bio Ltd (ZURA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Zura Bio Reports Third Quarter 2026 Financial Results and Recent Corporate Updates • TibuSHIELD topline data in hidradenitis suppurativa (HS) remains on track for Q4 2026; enrollment completed with 247 participants randomized, exceeding target • TibuSURE topline data
2 min readZura Bio (ZURA) reported a Q3 2026 net loss of $25.8M ($0.20/share) and had $187.7M in cash, expected to last through 2028. The company anticipates data catalysts in 2027 and a Phase 2 study for tibulizumab.
1 min readGuggenheim named Zura Bio a top pick in biotech, maintaining a Buy rating and $20 price target. The firm expects Phase II results for tibulizumab in hidradenitis suppurativa in Q4 2026, with potential for broader disease control. Guggenheim sees limited downside due to other pipeline assets and models peak sales of $1.6B for the drug. Analysts outline three scenarios with varying probabilities and implied stock prices.
1 min readZura Bio (ZURA) reported Q2 results, completing two Phase 2 trials ahead of schedule. Tibulizumab is being tested for three indications, with cash reserves expected to last until 2028. Net loss widened to $26.3M due to increased R&D spending. Hedge fund ownership declined, and short interest remains high at 15.95%.
2 min readZura Bio Ltd (ZURA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Zura Bio Reports Second Quarter 2026 Financial Results and Recent Corporate Updates • TibuSHIELD enrollment complete, exceeding initial enrollment target with 247 participants randomized in HS; topline data expected Q4 2026 • TibuSURE enrollment complete, exceeding i
4 min readThe article highlights 10 growth stocks with increased insider ownership, using a Finviz screen and criteria including at least 20% compounded earnings growth over three years. It cites analyst actions and company updates for Sonida Senior Living (SNDA) and Zura Bio (ZURA), including SNDA price target raises to $48 and ZURA Phase 2 enrollment and $225.6M cash.
7 min readZura Bio (NASDAQ:ZURA) is advancing tibulizumab. According to analyst Matt Phipps, the drug’s dual inhibition of T- and B-cell inflammatory pathways could improve outcomes in autoimmune diseases. Zura completed Phase 2 enrollment in TibuSHIELD for hidradenitis suppurativa, with topline data expected in Q4 2026; TibuSURE in 1H 2027. Phipps projects $2.3B peak HS sales (NPV $8.04/share) and William Blair projects $1.6B peak SSc sales (NPV $4.51/share). Zura reported $225.6M cash as of Mar 31, 2026
4 min readClear Street names five biotech stocks for 2H 2026 catalysts: MoonLake (MLTX) Buy, $70 target; Cullinan (CGEM) Buy, $46; Zura Bio (ZURA) Buy, $18; Arrivent (AVBP) Buy, $47; Protagonist (PTGX) Buy, $116. It cites planned clinical readouts and regulatory milestones, plus MLTX’s ~$200M offering and AVBP’s up to $250M ATM filing.
7 min readZura Bio Ltd (ZURA) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. EX-10.1 2 tm2618327d1_ex10-1.htm EXHIBIT 10.1 Exhibit 10.1 ZURA BIO LIMITED 2023 EQUITY INCENTIVE PLAN (As Amended June 1, 2023 and June 17, 2026) 1. Purpose The purpose of this Zura Bio Limited 2023 Equity Incentive Plan (the “ Plan ”) is to promote and closely align the interes
3 min read
